» Articles » PMID: 30697461

Utility of Metabolic Heterogeneity Factor in Differentiating Malignant Versus Benign Parotid Uptake on F FDG PET-CT

Overview
Date 2019 Jan 31
PMID 30697461
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Differentiation of benign and malignant parotid uptake on Fluorine 18 Fluro-Deoxy-Glucose Positron Emission Tomography-Computed Tomography (F FDG PET-CT) is of paramount importance due to the poor prognosis of the later but usual quantitative measures such as standardized uptake value (SUV) are not reliable for this purpose. Metabolic heterogeneity, being a characteristic of malignant tumors, would potentially be able to make this distinction. In this study, seventy-one FDG-avid parotid lesions were retrospectively separated histologically into benign and malignant groups. The heterogeneity factor (HF) of all the lesions was then calculated and compared between the two groups. There was significant difference in HF between malignant (median -0.17) and benign group (median -0.03); =0.0006. On receiver operating characteristic (ROC) analysis, a cut-off value of ≤ -0.06 for HF was associated with the highest sensitivity and specificity (sensitivity and specificity of 94.6% and 60.0%, respectively-AUC=0.789; =0.0001). Hence, it was concluded that HF is a reliable value in distinguishing benign from malignant parotid uptake on F FDG PET-CT.

Citing Articles

Differentiation of soft tissue and bone sarcomas from benign lesions utilizing F-FDG PET/CT-derived parameters.

Chen B, Feng H, Xie J, Li C, Zhang Y, Wang S BMC Med Imaging. 2020; 20(1):85.

PMID: 32711449 PMC: 7382845. DOI: 10.1186/s12880-020-00486-z.


Interobserver agreement of F-Fluorodeoxyglucose Positron-Emission Tomography combined with low-dose Computed Tomography for occult cancer screening in patients with unprovoked venous thromboembolism.

Robin P, Grewal R, Le Roux P, Le Gal G, Salaun P Thromb Res. 2020; 188:25-27.

PMID: 32036158 PMC: 7437657. DOI: 10.1016/j.thromres.2020.01.028.

References
1.
THOMLINSON R, GRAY L . The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer. 1955; 9(4):539-49. PMC: 2073776. DOI: 10.1038/bjc.1955.55. View

2.
Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M . Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med. 2005; 46(4):675-82. View

3.
Muylle K, Castaigne C, Flamen P . 18F-fluoro-2-deoxy-D-glucose positron emission tomographic imaging: recent developments in head and neck cancer. Curr Opin Oncol. 2005; 17(3):249-53. DOI: 10.1097/01.cco.0000160276.78762.17. View

4.
Pugachev A, Ruan S, Carlin S, Larson S, Campa J, Ling C . Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 2005; 62(2):545-53. DOI: 10.1016/j.ijrobp.2005.02.009. View

5.
Blodgett T, Fukui M, Snyderman C, Branstetter 4th B, McCook B, Townsend D . Combined PET-CT in the head and neck: part 1. Physiologic, altered physiologic, and artifactual FDG uptake. Radiographics. 2005; 25(4):897-912. DOI: 10.1148/rg.254035156. View